Aytu BioPharma (NASDAQ:AYTU) Shares Cross Below 50-Day Moving Average – Here’s What Happened

Aytu BioPharma Inc. (NASDAQ:AYTU)’s share price passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $2.15 and traded as low as $1.96. Aytu BioPharma shares last traded at $1.98, with a volume of 25,716 shares traded.

Wall Street Analyst Weigh In

AYTU has been the subject of a number of recent research reports. Citigroup reiterated a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Zacks Research lowered shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Finally, Weiss Ratings lowered shares of Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $14.50.

Aytu BioPharma Stock Up 1.0%

The firm has a market capitalization of $21.52 million, a PE ratio of -1.19 and a beta of 0.17. The company has a current ratio of 1.13, a quick ratio of 1.00 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average of $2.15 and a two-hundred day moving average of $2.24.

Institutional Investors Weigh In On Aytu BioPharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Aytu BioPharma in the 2nd quarter worth about $49,000. Persistent Asset Partners Ltd purchased a new stake in shares of Aytu BioPharma during the 2nd quarter worth about $82,000. Dimensional Fund Advisors LP grew its holdings in shares of Aytu BioPharma by 23.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after purchasing an additional 8,222 shares during the period. Arete Wealth Advisors LLC purchased a new stake in shares of Aytu BioPharma during the 1st quarter worth about $135,000. Finally, Crown Advisors Management Inc. acquired a new stake in Aytu BioPharma during the 2nd quarter worth approximately $430,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on developing and commercializing prescription medicines for pediatric and primary-care markets. The company’s portfolio includes treatments for attention-deficit/hyperactivity disorder (ADHD), along with products addressing allergies, respiratory conditions, and other common health needs.

Aytu’s ADHD portfolio has included orally disintegrating and liquid formulations designed for children and adolescents, such as Adzenys XR-ODT, Cotempla XR-ODT, and Dyanavel XR.